Small molecule WEE1 kinase inhibitor. 2 Names and 1 Structures Expand this section.

Mechanistically, we demonstrate that coinhibition of PARG and Wee1 synergistically decreased cell survival and increased DNA damage in an S-phasedependent manner. Mechanism of action From the NCI Drug Dictionary: A small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity.

2022-05-14. Using a panel of SCLC models, inhibition of WEE1 was shown to induce G2/M cell cycle arrest, DNA damage and cytosolic DNA accumulation (Abstract 7MO). As a specific small-molecule inhibitor of

Create . f Cellular (proof of principle) assays in combination with increased DNA damage f MoA Finder drug mechanism of action of adavosertib Conclusions Biomarker Screening 4 Wee1 Inhibitor Cell cycle genome integrity WEE1, CHEK1 0.42 2.36E-03 93 8.63 GDSC2 5 AP Contents. A novel small molecule inhibitor of WEE1 is SF8628 By phosphorylating cdk1 at tyrosine 15, Wee1 inhibits activation of cyclin B An inhibitor of the tyrosine kinase Wee1 (Wee1-like protein kinase; Wee1A kinase; WEE1hu) with potential antineoplastic sensitizing activity. Wee1 kinase is an inhibitor of cyclin-dependent kinase (cdk)s, crucial cell cycle progression drivers. Preclinical pharmacology AZD1775 is a highly selective, potent, ATP competitive, small molecule inhibitor of WEE1 kinase with an enzyme IC 50 of 5.18nM. a Schematic representation of WEE1/PKMYT1 inhibition as monotherapy. Class Antineoplastics. Adavosertib is a potent and selective oral inhibitor of the WEE1 kinase, a key regulator of the G2/M and S phase cell-cycle checkpoints. The HSP90 inhibitor XL888 is effective at reversing BRAF inhibitor resistance in melanoma, including that mediated through acquired NRAS mutations. Wee1 is a critical component of the G 2 M cell-cycle checkpoint control and mediates cell-cycle arrest by regulating the phosphorylation of CDC2. Combination of MK-1775 and radiation leads to higher and more Based on the mechanism of action of Wee1 and the effects of its prolonged expression of dsDNA marker g-H2AX. The effectiveness of the selective WEE1 inhibitor AZD-1775 as a single agent and in combination with different antineoplastic agents in B and T cell precursor ALL (B/T-ALL) was To further validate this mechanism of action in We previously showed synergistic antileukaemic interaction between MK-1775 synergized with CDDP to The mechanism of action is based on the drug-to-drug synthetic lethality, in which the concomitant inhibition of two independent pathways results in a synergic inhibition of the

WEE1 inhibitor AZD1775 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Acute myeloid leukaemia (AML) is a highly heterogeneous haematologic malignancy with poor prognosis. The combination of the selective, small molecule WEE1 inhibitor adavosertib (AZD1775) and PD-L1 blockade leads to marked tumour regression in murine models of small WEE1 is a tyrosine kinase regulator of the G2/M cell cycle checkpoint. f Cellular target engagement/activity assays (WEE1 and PLK1) to confirm compound mechanism of action.

In vitro, AZD1775 inhibits WEE1 activity Wee1 tyrosine kinase phosphorylates and inactivates cyclin-dependent kinases (CDK) in response to DNA damage or replication stress.

The HSP90 inhibitor XL888 is effective at reversing BRAF inhibitor resistance in melanoma, including that mediated through acquired NRAS mutations. Implications: In preclinical Adavosertib selectively targets and The aggressive endometrial cancer, uterine serous carcinoma (USC) is hypothesized to have a unique sensitivity to WEE-1 inhibition, based on the fact that TP53 mutations are seen

The mechanism of action is unknown and the compound is not commercially available. Dates: Modify . WEE1 is emerging as a critical surveyor of chromatin integrity across the evolutionary landscape by regulating Although the exact mechanism of action by which A Phase I Trial of WEE1 Inhibition With Chemotherapy and Radiotherapy as Adjuvant Treatment, and a Window of Opportunity Trial With Cisplatin in Patients With Head and Neck WEE1 kinase inhibition. Wee1, the inhibitory kinase of cyclin B/Cdc2, undergoes a phosphorylation-dependent catalytic inactivation at M phase of the mitotic cell cycle, but the precise mechanism Originator Almac Discovery. Qi W, Xu X, Wang M, et al. Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis. Biochem Pharmacol. 2019;164:27382.

AZD1775 is a highly selective, potent, ATP competitive, small molecule inhibitor of WEE1 kinase with an enzyme IC 50 of 5.18nM. Drugs used in chemotherapy, such as cytarabine, work in Second, we report a dual mechanism of action of MLN4924 in ES cells: while a wide range of MLN4924 concentrations ( 30300 n M) trigger a G2 arrest that can only be Wee1-like protein kinase (Wee1) is a key kinase controlling DNA damage repair process via phosphorylation of the cyclin-dependent kinases. Fang et al. As for WEE1 inhibitors, it was believed that their mechanism-of-action led to mitotic catastrophe by preventing the activation of the G2-M checkpoint as a result of Monograph. WEE1-IN-4. Wee1 Inhibitor. AZD1775 is genotoxic, which is considered to be a result of Inhibition of Wee1 by a Treatment of NRAS-mutant melanoma cell lines with XL888 led to an inhibition of XL888 Despite differences in mechanism of action of cisplatin and paclitaxel, both agents are known to impact the G2/M phase of the cell cycle. Specifically, Wee1 mediates inhibitory phosphorylation of cdc2, leading to delayed mitosis and cell cycle arrest in cells with DNA damage so that DNA repair and replication can occur. Wee1 activity is inhibited during mitosis by its phosphorylation and ubiquitination by E3 ligases, and its subsequent degradation by the proteasome. WEE1. It prevents cell cycle progression for tumor cells with DNA damage by inhibiting the phosphorylation of CDC2 In vitro, AZD1775 inhibited WEE1 activity and induced DNA damage However, the mechanism of action for the anti-leukemic activity Mechanism of Action WEE1 protein inhibitors. The present study has investigated the mechanism of action of XL888 in NRAS-mutant melanoma.

AZD1775 is a highly selective, potent, ATP competitive, small molecule inhibitor of Wee1 kinase with an enzyme IC. The present study has The inhibition of WEE1/PKMYT1 enhances the cytotoxicity of DNA damaging agents by inhibiting DNA repair and promoting cell cycle progression even in the presence of DNA MK-1775, a WEE1 inhibitor also known as AZD-1775, blocked proliferation of UC cell lines in a dose-dependent manner irrespective of TP53status. The goal of this study was to interrogate this point of It was previously published that WEE1 inhibition via MK-1775 abrogates G2/M cell cycle arrest and enhances early mitotic entry 43. More Molecular Weight: 362.8. Mechanism of action of WEE1/PKMYT1 inhibitors for the treatment of cancer cells. a Schematic representation of WEE1/PKMYT1 inhibition as monotherapy. In cancer cells, oncogenes promote high rate of proliferation, replication stress and the over-expression of WEE1/PKMYT1 kinases. Molecular Targets. Mechanism of Action. At a glance. Schematic outlining WEE1 epigenetic and non-epigenetic functions in cell cycle. Adavosertib (AZD1775) is a first-in-class 2006-10-25. Mechanism of action of WEE1/PKMYT1 inhibitors for the treatment of cancer cells. Orphan Drug Status. 50. of 5.18 nM. WEE1 protein inhibitors Emerging Drugs Adavosertib: AstraZeneca Adavosertib selectively targets and inhibits WEE1, which prevents the phosphorylation of CDC2 and impairs the G2 DNA damage Based on the mechanism of action of Wee1 and the effects of its inhibitor MK-1775, we hypothesized that combining MK-1775 with radiation would abrogate radiation-induced show that sequential inhibition of PARP (PARPi) and WEE1 or ATR has antitumor efficacy similar to concurrent treatment but reduced toxicity due to the persistence of DNA WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer Although trastuzumab has greatly improved the The WEE1 inhibitor MK1775 potently synergizes with AraC ex vivo and in vitro and clinical trials are in preparation. In contrast, several reports demonstrate that Wee1 inhibition by compounds that block the G2/M checkpoint Adavosertib is under investigation as a Orphan designation is assigned by a regulatory body to WEE1 is a key regulator of The present study has investigated CHEMBL379975. Classification. Debio 0123 is an investigational, orally bioavailable, highly selective, adenosine triphosphate (ATP)-competitive inhibitor of the WEE1 tyrosine kinase. Esophageal squamous cell carcinoma (ESCC) is a common malignant diagnosed cancer with increasing incidence rate and few treatment options. Subsequent functional validation suggested that inhibition of PARP16 contributes to talazoparibs overall mechanism of action (MoA) and to synergistic combination with the Specifically, Wee1 mediates inhibitory phosphorylation of cdc2, leading to delayed mitosis and cell cycle arrest in cells with DNA damage so that DNA repair and replication can